Dipyridamole for Low Phosphate
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether Dipyridamole can help individuals with low phosphate levels following a kidney transplant. The researchers aim to determine if it can improve phosphate levels and reduce the need for additional supplements. Participants will receive either Dipyridamole with their usual post-transplant care or just the standard care. Suitable candidates for this trial are adult kidney transplant patients who tolerate Dipyridamole and do not require specific blood-thinning medications. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial requires that you stop taking Plavix, direct oral anticoagulants (DOACs), or Coumadin if you are currently using them.
Is there any evidence suggesting that Dipyridamole is likely to be safe for humans?
Earlier studies have used Dipyridamole in both children and adults for issues related to phosphate levels, and these studies did not find any major safety problems. Research also shows that Dipyridamole can improve kidney function and increase survival rates in people with chronic kidney disease, suggesting it is generally safe to use. Since this trial is in an early stage, Dipyridamole has shown some safety in humans, but more testing is needed to confirm its safety and effectiveness for this specific purpose.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for low phosphate, which often focus on dietary adjustments and phosphate supplements, Dipyridamole offers a novel approach. This drug is unique because it works by enhancing blood flow and potentially improving phosphate absorption at the cellular level. Researchers are excited about Dipyridamole because it not only complements the standard post-transplant care but may also provide a more efficient way to manage phosphate levels, potentially reducing the need for high doses of supplements. This could lead to better patient outcomes and fewer side effects associated with current treatments.
What evidence suggests that Dipyridamole might be an effective treatment for low phosphate?
Research has shown that dipyridamole can help improve low phosphate levels. In this trial, participants in the treatment group will receive dipyridamole alongside standard post-transplant care. One study found that patients who took 75 mg of dipyridamole four times a day had better phosphate levels and lost less phosphate through their kidneys. Another study found that adding dipyridamole to a treatment plan helped normalize both phosphorus and calcium levels. However, research in children did not show any change in phosphate levels with dipyridamole. Overall, dipyridamole has been linked to better kidney health, especially in adults.12467
Who Is on the Research Team?
Stephan Busque, MD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for kidney transplant recipients who may be at risk of developing low phosphate levels (hypophosphatemia) after their surgery. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and not have conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Dipyridamole in addition to standard post-transplant care
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dipyridamole
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor